Importantly, while not a cure, adding
a second targeted therapy could help improve treatments by overcoming drug resistance and extending the time before the cancer returns.
Not exact matches
What Stephen Hawking Missed: Small Biotechs Developing Promising Cell
Therapies for Devastating Disease Source: Streetwise Reports (5/2/18) In the
second of a two - part series exploring the disruptive cell
therapy space, Maxim Group analyst Jason McCarthy takes a look at small - cap companies
targeting big - ticket indications and their potential to drive blockbuster value for both patients and investors.
This webinar is the
second in a series (see Part 1 here) focusing on the cancer pathways that support tumor development, the emerging research in identifying and
targeting these pathways, and innovations in the development of increasingly effective cancer
therapy options.
As part of a
second trial, Swanton's lab will also study what happens to tumors under the selective pressure of various types of cancer
therapies, from traditional chemotherapy to
targeted drugs.
The
second branch of the combination
therapy, the low - dose metronomic chemotherapy, was similarly found to exert its therapeutic effect through a novel, hitherto unrecognized mechanism: The metronomic chemotherapy turned out to not primarily
target the tumor cells, but to act on the recruitment of yet another tumor - promoting cell population from the bone marrow.
So, for example, if one type of immunotherapy is used to knock out an inhibitory signal produced by a cancer, and the tumor responds by upregulating a
second signal, an additional
therapy could then be used to
target this one as well, Lu says.
These
therapies, the first an antibody and the
second of a class called tyrosine kinase inhibitors (TKIs), reduce the ability of a
target gene to manufacture the protein it encodes.
By developing a CAR T - cell
therapy that
targets a
second target on malignant cells, it may help leukemia patients whose cancer cells lack the C19 molecule or lose it.